nach oben

Wiener Medizinische Wochenschrift

Erschienen in:

01.11.2014 | main topic

Expression and putative functions of melatonin receptors in malignant cells and tissues

verfasst von: Cem Ekmekcioglu

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 21-22/2014

Einloggen, um Zugang zu erhalten

Summary

Melatonin, the popular hormone of the darkness, is primarily synthesized in the pineal gland, and acts classically through the G-protein coupled plasma membrane melatonin receptors MT₁ and MT₂, respectively. Although some of the receptor mediated functions of melatonin, especially those on the (central) circadian system, have been more or less clarified, the functional meaning of MT-receptors in various peripheral organs are still not sufficiently investigated yet. There is, however, accumulating evidence for oncostatic effects of melatonin with both, antioxidative and MT-receptor mediated mechanisms possibly playing a role. This review briefly summarizes the physiology of melatonin and MT-receptors, and discusses the expression and function of MT-receptors in human cancer cells and tissues.

Vorheriger Artikel Interplay of drug metabolizing enzymes with cellular transporters

Nächster Artikel Epithelial ovarian cancer - more data, more questions?

Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin, a pineal factor that lightens melanocytes. J Am Chem Soc. 1958;80:2057–8.

Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.PubMed

Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, et al. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol. 2012;351:152–66.PubMedCentralPubMed

Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocrine reviews. 1991;12:151–80.PubMed

Allegra M, Reiter RJ, Tan DX, et al. The chemistry of melatonin’s interaction with reactive species. J Pineal Res. 2003;34:1–10.PubMed

Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003;34:75–8.PubMed

Pandi-Perumal SR, BaHammam AS, Brown GM, et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013;23:267–300.PubMed

Benitez-King G, Anton-Tay F. Calmodulin mediates melatonin cytoskeletal effects. Experientia. 1993;49:635–41.PubMed

Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, et al. Involvement of nuclear binding sites for melatonin in the regulation of il-2 and il-6 production by human blood mononuclear cells. J Neuroimmunol. 1998;92:76–84.PubMed

10.

Steinhilber D, Brungs M, Werz O, et al. The nuclear receptor for melatonin represses 5-lipoxygenase gene expression in human b lymphocytes. J Biol Chem. 1995;270:7037–40.PubMed

11.

Dubocovich ML, Delagrange P, Krause DN, et al. International union of basic and clinical pharmacology. Lxxv. Nomenclature, classification, and pharmacology of g protein-coupled melatonin receptors. Pharmacol Rev. 2010;62:343–80.PubMedCentralPubMed

12.

Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, et al. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci. 2003;8:d1093–108.PubMed

13.

Barrett P, Conway S, Morgan PJ. Digging deep–structure-function relationships in the melatonin receptor family. J Pineal Res. 2003;35:221–30.PubMed

14.

New DC, Tsim ST, Wong YH. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals. 2003;12:59–70.PubMed

15.

Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE. 2001;2001:PE39.PubMed

16.

Jiang ZG, Nelson CS, Allen CN. Melatonin activates an outward current and inhibits ih in rat suprachiasmatic nucleus neurons. Brain Res. 1995;687:125–32.PubMed

17.

Ben Soussia I, Mies F, Naeije R, et al. Melatonin down-regulates volume-sensitive chloride channels in fibroblasts. Pflugers Arch. 2012;464:273–85.PubMed

18.

Reppert SM, Godson C, Mahle CD, et al. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734–8.PubMedCentralPubMed

19.

Petit L, Lacroix I, de Coppet P, et al. Differential signaling of human mel1a and mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol. 1999;58:633–9.PubMed

20.

Hunt AE, Al-Ghoul WM, Gillette MU, et al. Activation of mt(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol Cell Physiol. 2001;280:C110–8.PubMed

21.

Ayoub MA, Couturier C, Lucas-Meunier E, et al. Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem. 2002;277:21522–8.PubMed

22.

Mailliet F, Ferry G, Vella F, et al. Organs from mice deleted for nrh:Quinone oxidoreductase 2 are deprived of the melatonin binding site mt3. FEBS Lett. 2004;578:116–20.PubMed

23.

Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site mt3 as the quinone reductase 2. J Biol Chem. 2000;275:31311–7.PubMed

24.

Pintor J, Pelaez T, Hoyle CH, et al. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: Further evidence for an mt3 receptor. Br J Pharmacol. 2003;138:831–6.PubMedCentralPubMed

25.

Reppert SM, Weaver DR, Ebisawa T, et al. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996;386:219–24.PubMed

26.

von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151–62.PubMed

27.

Witt-Enderby PA, Bennett J, Jarzynka MJ, et al. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci. 2003;72:2183–98.PubMed

28.

Ekmekcioglu C. Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother. 2006;60:97–108.PubMed

29.

Weaver DR, Reppert SM. The mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport. 1996;8:109–12.PubMed

30.

Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.PubMed

31.

Okamura H, Doi M, Fustin JM, et al. Mammalian circadian clock system: molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev. 2010;62:876–84.PubMed

32.

Imbesi M, Arslan AD, Yildiz S, et al. The melatonin receptor mt1 is required for the differential regulatory actions of melatonin on neuronal ‘clock’ gene expression in striatal neurons in vitro. J Pineal Res. 2009;46:87–94.PubMed

33.

Nemeth C, Humpeler S, Kallay E, et al. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011;25:531–42.PubMed

34.

Arendt J, Skene DJ, Middleton B, et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997;12:604–17.PubMed

35.

Spadoni G, Bedini A, Rivara S, et al. Melatonin receptor agonists: New options for insomnia and depression treatment. CNS Neurosci Ther. 2011;17:733–41.PubMed

36.

Zhdanova IV. Melatonin as a hypnotic: Pro. Sleep Med Rev. 2005;9:51–65.PubMed

37.

Uchikawa O, Fukatsu K, Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem. 2002;45:4222–39.PubMed

38.

Wu YH, Ursinus J, Zhou JN, et al. Alterations of melatonin receptors mt1 and mt2 in the hypothalamic suprachiasmatic nucleus during depression. J Affect Disord. 2013;148:357–67.PubMed

39.

Hickie IB, Rogers NL. Novel melatonin-based therapies: Potential advances in the treatment of major depression. Lancet. 2011;378:621–31.PubMed

40.

Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (s20098) is an antagonist at 5-hydroxytryptamine 2c receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–64.PubMed

41.

Savaskan E, Olivieri G, Meier F, et al. Increased melatonin 1a-receptor immunoreactivity in the hippocampus of alzheimer’s disease patients. J Pineal Res. 2002;32:59–62.PubMed

42.

Uz T, Arslan AD, Kurtuncu M, et al. The regional and cellular expression profile of the melatonin receptor mt1 in the central dopaminergic system. Brain Res Mol Brain Res. 2005;136:45–53.PubMed

43.

Scher J, Wankiewicz E, Brown GM, et al. Mt(1) melatonin receptor in the human retina: Expression and localization. Invest Ophthalmol Vis Sci. 2002;43:889–97.PubMed

44.

Ekmekcioglu C, Haslmayer P, Philipp C, et al. 24h variation in the expression of the mt1 melatonin receptor subtype in coronary arteries derived from patients with coronary heart disease. Chronobiol Int. 2001;18:973–85.PubMed

45.

Ekmekcioglu C, Haslmayer P, Philipp C, et al. Expression of the mt1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001;21:85–91.PubMed

46.

Ekmekcioglu C, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype mt2 is present in the human cardiovascular system. J Pineal Res 2003;35:40–4.PubMed

47.

Aust S, Thalhammer T, Humpeler S, et al. The melatonin receptor subtype mt1 is expressed in human gallbladder epithelia. J Pineal Res. 2004;36:43–8.PubMed

48.

Toma CD, Svoboda M, Arrich F, et al. Expression of the melatonin receptor (mt) 1 in benign and malignant human bone tumors. J Pineal Res. 2007;43:206–13.PubMed

49.

Rogelsperger O, Wlcek K, Ekmekcioglu C, et al. Melatonin receptors, melatonin metabolizing enzymes and cyclin d1 in human breast cancer. J Recept Signal Transduct Res. 2011;31:180–7.PubMed

50.

Rogelsperger O, Ekmekcioglu C, Jager W, et al. Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res. 2009;46:422–32.PubMed

51.

Yang Q, Scalbert E, Delagrange P, et al. Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries. Am J Physiol Heart Circ Physiol. 2001;280:H76–82.

52.

Masana MI, Doolen S, Ersahin C, et al. Mt(2) melatonin receptors are present and functional in rat caudal artery. J Pharmacol Exp Ther. 2002;302:1295–302.PubMed

53.

Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: Effects of postural change and melatonin administration. J Appl Physiol. 1997;83:134–9.PubMed

54.

van den Heuvel CJ, Kennaway DJ, Dawson D. Thermoregulatory and soporific effects of very low dose melatonin injection. Am J Physiol. 1999;276:E249–54.

55.

Cook JS, Sauder CL, Ray CA. Melatonin differentially affects vascular blood flow in humans. Am J Physiol Heart Circ Physiol. 2011;300:H670–4.

56.

Arangino S, Cagnacci A, Angiolucci M, et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol. 1999;83:1417–9.PubMed

57.

Raikhlin NT, Kvetnoy IM, Tolkachev VN. Melatonin may be synthesised in enterochromaffin cells. Nature. 1975;255:344–5.PubMed

58.

Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest. 2001;108:625–33.PubMedCentralPubMed

59.

Le Gouic S, Delagrange, Atgie C, et al. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obes Relat Metab Disord. 1996;20:661–7.PubMed

60.

Viswanathan M, Hissa R, George JC. Effects of short photoperiod and melatonin treatment on thermogenesis in the syrian hamster. J Pineal Res. 1986;3:311–21.PubMed

61.

Kozirog M, Poliwczak AR, Duchnowicz P, et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011;50:261–6.PubMed

62.

Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: Interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14:6981–7015.PubMedCentralPubMed

63.

Peschke E, Schucht H, Muhlbauer E. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both wistar and type 2-diabetic goto-kakizaki rats. J Pineal Res. 2010;49:373–81.PubMed

64.

Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near mtnr1b is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94.PubMed

65.

Chambers JC, Zhang W, Zabaneh D, et al. Common genetic variation near melatonin receptor mtnr1b contributes to raised plasma glucose and increased risk of type 2 diabetes among indian asians and european caucasians. Diabetes. 2009;58:2703–8.PubMedCentralPubMed

66.

Xia Q, Chen ZX, Wang YC, et al. Association between the melatonin receptor 1b gene polymorphism on the risk of type 2 diabetes, impaired glucose regulation: a meta-analysis. PLoS One. 2012;7:e50107.PubMedCentralPubMed

67.

Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, et al. Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem. 2010;17:4462–81.PubMed

68.

Cutando A, Lopez-Valverde A, Arias-Santiago S, et al. Role of melatonin in cancer treatment. Anticancer Res. 2012;32:2747–53.PubMed

69.

Cohen M, Lippman M, Chabner B. Pineal gland and breast cancer. Lancet. 1978;2:1381–2.PubMed

70.

Bartsch C, Bartsch H, Jain AK, et al. Urinary melatonin levels in human breast cancer patients. J Neural Transm. 1981;52:281–94.PubMed

71.

Haus EL, Smolensky MH. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev. 2013;17:273–84.PubMed

72.

Hansen J, Lassen CF. Nested case-control study of night shift work and breast cancer risk among women in the danish military. Occup Environ Med. 2012;69:551–6.PubMed

73.

Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2008;100:898–905.PubMedCentralPubMed

74.

Proietti S, Cucina A, Reiter RJ, et al. Molecular mechanisms of melatonin’s inhibitory actions on breast cancers. Cell Mol Life Sci. 2013;70:2139–57.PubMed

75.

Yuan L, Collins AR, Dai J, et al. Mt(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol. 2002;192:147–56.PubMed

76.

Dillon DC, Easley SE, Asch BB, et al. Differential expression of high-affinity melatonin receptors (mt1) in normal and malignant human breast tissue. Am J Clin Pathol. 2002;118:451–8.PubMed

77.

Garcia Pedrero JM, Del Rio, Martinez-Campa C, et al. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol. 2002;16:947–60.PubMed

78.

Cos S, Gonzalez A, Martinez-Campa C, et al. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 2006;30:118–28.PubMed

79.

Mediavilla MD, Cos S, Sanchez-Barcelo EJ. Melatonin increases p53 and p21waf1 expression in mcf-7 human breast cancer cells in vitro. Life Sci. 1999;65:415–20.PubMed

80.

Santoro R, Mori F, Marani M, et al. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 2013;34:1051–61.PubMed

81.

Cos S, Blask DE, Lemus-Wilson A, et al. Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of mcf-7 human breast cancer cells in culture. J Pineal Res. 1991;10:36–42.PubMed

82.

Kauppila A, Kivela A, Pakarinen A, et al. Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity. J Clin Endocrinol Metab. 1987;65:823–8.PubMed

83.

Hill SM, Blask DE, Xiang S, et al. Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia. 2011;16:235–45.PubMed

84.

Jablonska K, Pula B, Zemla A, et al. Expression of melatonin receptor mt1 in cells of human invasive ductal breast carcinoma. J Pineal Res. 2013;54:334–45.PubMed

85.

Oprea-Ilies G, Haus E, Sackett-Lundeen L, et al. Expression of melatonin receptors in triple negative breast cancer (tnbc) in african american and caucasian women: relation to survival. Breast Cancer Res Treat. 2013;137:677–87.PubMedCentralPubMed

86.

GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.Iarc.fr. Accessed 7 July 2014

87.

Shiu SY. Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment. J Pineal Res. 2007;43:1–9.PubMed

88.

Joo SS, Yoo YM. Melatonin induces apoptotic death in lncap cells via p38 and jnk pathways: therapeutic implications for prostate cancer. J Pineal Res. 2009;47:8–14.PubMed

89.

Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al. Melatonin, a novel sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in tramp model. J Pineal Res. 2011;50:140–9.PubMedCentralPubMed

90.

Xi SC, Tam PC, Brown GM, et al. Potential involvement of mt1 receptor and attenuated sex steroid-induced calcium influx in the direct anti-proliferative action of melatonin on androgen-responsive lncap human prostate cancer cells. J Pineal Res. 2000;29:172–83.PubMed

91.

Tam CW, Chan KW, Liu VW, et al. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance. J Pineal Res. 2008;45:403–12.PubMed

92.

Gilad E, Laudon M, Matzkin H, et al. Functional melatonin receptors in human prostate epithelial cells. Endocrinology. 1996;137:1412–7.PubMed

93.

Laudon M, Gilad E, Matzkin H, et al. Putative melatonin receptors in benign human prostate tissue. J Clin Endocrinol Metab. 1996;81:1336–42.PubMed

94.

Tam CW, Shiu SY. Functional interplay between melatonin receptor-mediated antiproliferative signaling and androgen receptor signaling in human prostate epithelial cells: potential implications for therapeutic strategies against prostate cancer. J Pineal Res. 2011;51:297–312.PubMed

95.

Tam CW, Mo CW, Yao KM, et al. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res. 2007;42:191–202.PubMed

96.

Fernandez PL, Arce Y, Farre X, et al. Expression of p27/kip1 is down-regulated in human prostate carcinoma progression. J Pathol. 1999;187:563–6.PubMed

97.

Rimler A, Culig Z, Levy-Rimler G, et al. Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. The Prostate. 2001;49:145–54.PubMed

98.

Kos-Kudla B, Ostrowska Z, Kozlowski A, et al. Circadian rhythm of melatonin in patients with colorectal carcinoma. Neuro Endocrinol Lett. 2002;23:239–42.PubMed

99.

Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst. 2003;95:825–8.PubMed

100.

Farriol M, Venereo Y, Orta X, et al. In vitro effects of melatonin on cell proliferation in a colon adenocarcinoma line. J Appl Toxicol. 2000;20:21–4.PubMed

101.

Slominski A, Pisarchik A, Semak I, et al. Serotoninergic and melatoninergic systems are fully expressed in human skin. Faseb J. 2002;16:896–8.PubMed

102.

Slominski A, Pisarchik A, Zbytek B, et al. Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol. 2003;196:144–53.PubMed

103.

Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/melatoninergic system: Securing a place under the sun. Faseb J. 2005;19:176–94.PubMed

104.

Hu DN, Roberts JE. Melatonin inhibits growth of cultured human uveal melanoma cells. Melanoma Res. 1997;7:27–31.PubMed

105.

Ying SW, Niles LP, Crocker C. Human malignant melanoma cells express high-affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol. 1993;246:89–96.PubMed

106.

Cabrera J, Negrin G, Estevez F, et al. Melatonin decreases cell proliferation and induces melanogenesis in human melanoma sk-mel-1 cells. J Pineal Res. 2010;49:45–54.PubMed

107.

Danielczyk K, Dziegiel P. The expression of mt1 melatonin receptor and ki-67 antigen in melanoma malignum. Anticancer Res. 2009;29:3887–95.PubMed

108.

Kleszczynski K, Fischer TW. Melatonin and human skin aging. Dermatoendocrinol. 2012;4:245–52.PubMedCentralPubMed

Titel: Expression and putative functions of melatonin receptors in malignant cells and tissues
verfasst von: Cem Ekmekcioglu
Publikationsdatum: 01.11.2014
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 21-22/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-014-0289-6

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 21-22/2014

Translational hematology

Erratum to: Hepatocellular carcinoma

Epithelial ovarian cancer - more data, more questions?

A short update on cancer chemoresistance

Toward new targets for the diagnosis and treatment of malignant diseases

Hepatocellular carcinoma